GlassScriptPhysician profile
Weiping Zang
NPI 1366722787
$1,182.43
in general payments reported to CMS, 2019-2025
20 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $11.62 · 2021: $134 · 2022: $158 · 2023: $90.87 · 2024: $21.87 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.45 |
| Education | $123.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $242.89 | 2019-2022 | |
| Boston Scientific Corporation | $163.81 | 2025 | Ams 700 |
| Pfizer INC. | $148.20 | 2019-2025 | |
| Genentech USA, INC. | $119.03 | 2019-2025 | |
| Amgen INC. | $50.64 | 2019-2022 | |
| Abbvie INC. | $49.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.83 | 2019-2023 | Opdivo |
| Exelixis INC. | $45.80 | 2025 | Cabometyx |
| Genzyme Corporation | $45.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $43.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $37.28 | 2019 | |
| Spectrum Pharmaceuticals INC. | $29.94 | 2023 | Rolvedon |
| Takeda Pharmaceuticals U.S.A., INC. | $29.93 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $25.44 | 2019 | |
| Tempus Ai, INC | $21.87 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.99 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $18.60 | 2025 | Sancuso |
| Regeneron Healthcare Solutions, INC. | $16.24 | 2023 | Libtayo |
| Tactile Systems Technology INC | $14.78 | 2023 | Entre Plus, Flexitouch Plus |
| Cti Biopharma Corp. | $13.33 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiping Zang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.